Edwards Lifesciences Corporation (EW)
Automate Your Wheel Strategy on EW
With Tiblio's Option Bot, you can configure your own wheel strategy including EW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EW
- Rev/Share 9.4374
- Book/Share 17.1459
- PB 4.3426
- Debt/Equity 0.07
- CurrentRatio 4.1758
- ROIC 0.114
- MktCap 43396668000.0
- FreeCF/Share 0.494
- PFCF 149.6953
- PE 10.3855
- Debt/Assets 0.0536
- DivYield 0
- ROE 0.4904
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 2
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | EW | Piper Sandler | Neutral | Overweight | -- | $80 | April 24, 2025 |
| Upgrade | EW | Stifel | Hold | Buy | $75 | $90 | Jan. 30, 2025 |
| Downgrade | EW | Wolfe Research | Peer Perform | Underperform | -- | $60 | Jan. 16, 2025 |
| Upgrade | EW | BofA Securities | Neutral | Buy | -- | -- | Dec. 16, 2024 |
| Resumed | EW | Morgan Stanley | -- | Equal Weight | -- | $70 | Oct. 11, 2024 |
| Downgrade | EW | Jefferies | Buy | Hold | $85 | $70 | Sept. 18, 2024 |
News
Edwards Lifesciences: With A Heart Beating Strong And Steady
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Positive
Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&P 500 averages.
Read More
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Read More
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco.
Read More
Trade Tracker: Bill Baruch buys Edwards Lifesciences
Published: May 19, 2025 by: CNBC Television
Sentiment: Positive
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.
Read More
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
Read More
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible lat.
Read More
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens
Published: April 24, 2025 by: Benzinga
Sentiment: Positive
Edwards Lifesciences‘ EW shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion.
Read More
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
Read More
Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovighian - Chief Executive Officer Scott Ullem - Corporate Vice President and Chief Financial Officer Daveen Chopra - Corporate Vice President, TMTT Larry Wood - Corporate Vice President and Group President of TAVR and SSH Conference Call Participants David Roman - Goldman Sachs Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Travis Steed - Bank of America Vijay Kumar - Evercore ISI Frederick Wise - Stifel Matthew …
Read More
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
About Edwards Lifesciences Corporation (EW)
- IPO Date 2000-03-27
- Website https://www.edwards.com
- Industry Medical - Devices
- CEO Mr. Bernard J. Zovighian
- Employees 15800